
    
      Participants receiving MK-5890 monotherapy who experience disease progression may be eligible
      to switch to receiving MK-5890 plus pembrolizumab combination therapy for up to 35 cycles
      (approximately 2 years) at the discretion of the Investigator and approval of the Sponsor.
    
  